Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
Anti-Androgen Monotherapy
Zytiga approved for metastatic prostate cancer
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
New drugs, new thinking for prostate cancer
Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.
Some breast cancers may respond to anti-androgen drug
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
Annual report highlights 2012 cancer advances
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.
Bladder cancer may respond to antiandrogen therapy
A protein that confers a worse prognosis in bladder cancer when present in high levels may respond to antiandrogen therapy used in prostate cancer.
New drugs change treatment landscape for advanced prostate cancer
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Prostate cancer treatments and heart disease risk
Hormone therapy for prostate cancer increases men’s risk of dying from heart disease, but the additional risk varies almost sevenfold for different treatments, a King’s College London study has found.
